Key Points for Decision Makers {#FPar1}
==============================

Accurate costs from the health service perspective can be precisely attached to the Clinical Practice Research Datalink (CPRD) and linked Hospital Episode Statistics (HES) data at an individual level, and these data can be used to calculate accurate total healthcare utilisation rates and costs.There are sufficient data available to allow multiple stratification that reflects patient heterogeneity.The outcomes generated from these methods at either an individual or cohort level can be used directly as input parameters for further economic modelling, which will enhance healthcare policy and decision making.

Introduction {#Sec1}
============

Health economic evaluations are becoming increasingly important in the decisions made regarding healthcare provision and policy. In many healthcare settings, funding for a service, drug or intervention is dependent on demonstrating its cost effectiveness. These evaluations require complete and detailed longitudinal data for large numbers of patients regarding the course of their health conditions, the consequences and the costs \[[@CR1]\]. Historically, this has been difficult to retrieve or compile. The increase in electronic collection of routine healthcare data means real-world data are becoming more available. Real-world evidence from electronic health records represents actual clinical practice and patient heterogeneity in a way not often reflected within randomised controlled trials (RCTs) \[[@CR2], [@CR3]\]. The large number of patients available for study provides the opportunity for subgroup stratification and assessment of rare diseases and outcomes, which is usually not possible with RCT data. An additional benefit is the many years of data available for each patient \[[@CR2]\].

Until recently, datasets have allowed analysis of only one aspect of patient care. These have included care from a single provider, only primary care, only inpatient or outpatient hospital care, or mortality. Recent developments in data linkage now allow analysis of the majority of healthcare accessed by patients in England across domains paid for by the National Health Service (NHS) \[[@CR4], [@CR5]\]. Detailed data for calculating healthcare cost according to the UK NHS payment and reimbursement system are also publically available \[[@CR6], [@CR7]\]. Combining these data offers new potential to assess complete utilisation and cost of healthcare from the perspective of the UK NHS as payer.

This study assesses the feasibility of using linked electronic health records to calculate the cost of healthcare utilisation across primary and secondary healthcare settings. In the UK, all secondary care is provided within a hospital setting. Our aim was to generate stratified utilisation and cost data that could be suitable input parameters for future economic modelling. To do this, we set out to answer the question "What is the effect on the pattern and cost of healthcare utilisation of a referral to see a gastroenterologist among people with irritable bowel syndrome (IBS)?".

IBS is a chronic, nonfatal condition, diagnosed in 11 % of the population \[[@CR8]\]. Patients experience abdominal pain with diarrhoea or constipation, or both, but they have no structural bowel abnormality. International guidelines recommend diagnosis of IBS according to clinical criteria within primary care with minimal investigation, and also recommend IBS management within primary care \[[@CR9]--[@CR12]\]. Despite this, up to 20 % of patients are referred to see a gastroenterologist \[[@CR13]\], and managing IBS constitutes between 25 and 50 % of gastroenterology outpatient workload \[[@CR14]--[@CR17]\]. Our study used linked electronic healthcare data from primary and secondary care in England to calculate rates and costs of healthcare utilisation for patients with IBS before and after their first appointment with a gastroenterologist.

Methods {#Sec2}
=======

Data Source {#Sec3}
-----------

The Clinical Practice Research Datalink (CPRD) is an anonymised longitudinal dataset of over 13 million medical records from over 640 primary care practices across the UK, collected prospectively from routine care since 1987 \[[@CR4], [@CR18]\]. It contains details of all primary care contact a person has had, the reason for the contact, who it was with and any medication prescribed. Records of almost two-thirds of English practices within the CPRD are linked to the NHS Hospital Episode Statistics (HES) \[[@CR4], [@CR5]\], which provide secondary care inpatient data from NHS hospitals in England since 1989 and outpatient data from 2004.

The cost to the health service of primary care utilisation is calculated nationally from unit costs, and is reported, along with social care costs, as NHS reference costs \[[@CR6]\]. Costs of medication prescribed in primary care are contained in the British National Formulary (BNF). In England, the cost of secondary care to the health service (the payer) is calculated according to national tariff prices, based on the national average unit costs of providing each service (published as the National Schedule of Reference Costs \[[@CR19]\]). The currency of patient activity used to attract a tariff is the Healthcare Resource Group (HRG) \[[@CR7]\]. This is calculated according to an algorithm that clusters diagnostic codes, treatments and procedures with similar resource implications \[[@CR7]\]. To generate the appropriate HRG code, secondary care events are grouped into spells, which include the different diagnoses made, the events that occurred during an admission, such as different specialists involved in care, procedures and investigations (not including blood tests), and the duration of care in different settings. The algorithm provides a hierarchy of the events coded within each spell, with adjustment for market factor forces and patient demographics, all of which are contained within the HES data. The National Casemix Office generates this algorithm and grouping software in order to attach the HRG data to the HES data \[[@CR7]\]. The HRGs are currently updated annually in line with the tariff. Consequently, like the tariff, HRGs are year-specific. This study uses one cohort to compare costs before and after an intervention. To ensure changes in cost were from changes in utilisation and not changes within the HRG algorithm or tariff rates, the same HRG grouping algorithm was used for data in all years. We used 2012/2013 HRGs and tariff as they were the most recent and most consistent with the latest data we had available. For consistency, we used the 2012 unit and reference costs.

Where tariff costs do not exist, usually for rare conditions or treatments, reference costs are generated from the national average of the unit cost of care \[[@CR19]\].

Irritable Bowel Syndrome (IBS) Cohort {#Sec4}
-------------------------------------

Construction of the initial cohort of patients with IBS has been fully described previously \[[@CR20]\]. Briefly, individuals with records audited to acceptable research quality (where the record is checked for concordant dates, demographic data and consistent registration \[[@CR18]\]) from CPRD practices with HES-linked data were identified as having IBS if they had a diagnostic (Read) code for IBS in either their CPRD clinical or referral file. The first event within the patient record explicitly coded as IBS defined the date of diagnosis. Patients were excluded if they had any diagnostic code for inflammatory bowel disease, colorectal cancer or coeliac disease recorded within their entire health record. Patients have one unique HES identifier for all their secondary care records across the UK. If a patient moves between CPRD primary care practices they receive a new identifier and their records within the CPRD are not linked. Multiple CPRD records with one HES identifier were excluded (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Process depicting how the cohort of patients with IBS referred to gastroenterology in 2008 or 2009 was constructed within the CPRD. *IBS* irritable bowel syndrome, *CPRD* Clinical Practice Research Datalink

The first gastroenterology appointment was defined as a patient's earliest recorded gastroenterology appointment within the HES outpatient data. The HES outpatient data are only available to link to CPRD records from 2004. Our datasets contained data until the end of 2012. To allow 3 full years of data for all healthcare domains before and after gastroenterology appointment, we selected those patients who had their first gastroenterology appointment in 2008 or 2009. Patients with fewer than 3 full years of data before or after the gastroenterology appointment were excluded.

Primary Care {#Sec5}
------------

Each primary care attendance was identified within the CPRD clinical file along with the professional with whom the consultation occurred. Appropriate reference costs were attached from the unit costs of health and social care \[[@CR6]\]. Where consultation type was unknown (8.5 % of all consultations across the entire study period), a weighted average of the costs of the different consultation types available was used. This was calculated by summing the product of the proportion of each consultation type and its cost in each year.

Prescriptions {#Sec6}
-------------

For each subject, we identified every separate prescription recorded in the CRPD prescriptions file. Drugs were classified according to their BNF chapter subparagraph, and the mean subparagraph cost was attached according to the 2012 England Prescription Cost Analysis (Health and Social Care Information Centre) \[[@CR21]\]. Where missing data for the specific drug supplied prevented this (0.04 % of prescriptions), we attributed the 2012 median prescription cost as reported in the Prescription Cost Analysis (£38.74) \[[@CR21]\].

Secondary Care {#Sec7}
--------------

HES outpatient data were used to identify each attendance and specialty. Costs were taken from the NHS 2012 tariff for outpatient care. Costs in the tariff differ if appointments are first or subsequent visits, which are coded in HES so appropriate costs were attributed. Within HES, the treatment function code represents the specialised service within which a patient is treated \[[@CR7], [@CR22]\]. Events were linked to cost through the treatment function code within the HES outpatient data. All attendances were considered as single-consultant appointments for costing purposes, not multidisciplinary team appointments. Outpatient appointments excluded from Payment by Results (the tariff system that reimburses healthcare providers in the NHS \[[@CR23]\]) in 2012, or occurring too infrequently at a national level, were not covered by the 2012 tariff. Costs for these appointments were taken from the unit price reported by appointment type in the 2012 reference costs \[[@CR19]\].

Hospital admissions, including both day case and inpatient spells, but excluding colonoscopy, were extracted from HES data. Each separate hospital spell was identified for each patient along with the main treatment specialty. Spells with day-case codes, or inpatient stays of 1-day duration, were considered as day-case admissions. The HES inpatient data were reformatted so that the NHS 2012 grouper could be used to generate the appropriate HRG for each spell using the hierarchical algorithm \[[@CR7]\]. These HRGs were linked to the 2012 NHS tariff costs. Elective or emergency prices were attached as appropriate and, if this status was unknown, elective prices were used. HRGs with no national tariff were identified and the appropriate price for each admission was attached from the 2012 reference costs \[[@CR19]\]. The mean cost of day-case attendance in 2012 was £682, and £3215 per stay for inpatient admission; these costs were used when no reference costs were available.

Colonoscopy {#Sec8}
-----------

Individual procedures can be specifically isolated and the cost attached. We identified colonoscopies in both the HES outpatient and hospital admissions data, and classified each procedure as elective or emergency according to coding in the dataset. The 2012 NHS tariff costs were attached.

Analysis {#Sec9}
--------

The duration of IBS before referral was defined as the time from the first IBS code in the patient record. Socioeconomic status within the CPRD dataset is on a patient postcode level \[[@CR4]\] and is defined according to the quintile of the index of multiple deprivation. Smoking status was defined as ever or never smokers. The full clinical data available within the CPRD and HES record until 31 December 2012 were used to identify comorbidities, and from these the Charlson index was calculated \[[@CR24]\]. For analysis, patients were classified as having no comorbidities (a score of 0) or comorbidities (a score of 1 or greater). Poisson regression analysis was used to generate adjusted rate ratios (RR), with robust standard errors used to produce 95 % confidence intervals (CI) for each of the domains of healthcare utilisation over the entire 6 years of data according to demographic strata. Three 1-year bands were defined for each patient before and after the date of the gastroenterology appointment, and the mean annual utilisation rates and costs were calculated. Rates of utilisation were approximately normally distributed and are presented in summary as mean and 95 % CI. Absolute differences in utilisation rate were calculated in each domain compared with the rate in the year 3 years before the gastroenterology appointment, and are presented with 95 % CIs. We hypothesised a priori that the use of healthcare might increase, leading to a referral to see a gastroenterologist for IBS, and fall afterwards. Consequently, we took 3 years before referral as the baseline year with which to compare utilisation rates. Absolute differences were reported as these were the most useful data for economic analyses. Mean individual annual costs by domain were calculated. The cost data best fit gamma distributions, therefore alpha and lambda parameters were calculated. The absolute cost difference and 95 % CI was calculated for total individual annual costs compared with the baseline year. Stratified overall annual mean costs and gamma distribution parameters were calculated according to sex, age at referral, duration of IBS, socioeconomic status, smoking status and comorbidity status. No costs were discounted. All analyses were conducted using Stata version 12 (StataCorp LP, College Station, TX, USA) \[[@CR25]\].

Results {#Sec10}
=======

Our original cohort identified 256,060 patient records that had been audited as acceptable for research from HES-linked CPRD practices, with IBS Read codes in either the clinical or referral file \[[@CR20]\]. No HES outpatient data were available for 13 % of cases. Linking the HES data to the CPRD records identified 4562 patients (2 %) with multiple CPRD identities. Duplicated records or inconsistent dates were found in 12 % of the HES outpatient records, and these patient records were entirely excluded as it was not possible to establish which data were accurate. Of the IBS patients identified, 11 % had a gastroenterology outpatient appointment between 2004 and 2012. Of these, 4809 had a first gastroenterology outpatient appointment in 2008 or 2009. Three full years of CPRD and HES data before and after the gastroenterology appointment were available for 2076 of these patients (Fig. [1](#Fig1){ref-type="fig"}). Table [1](#Tab1){ref-type="table"} shows the demographic data for this cohort. The median duration of IBS before a first gastroenterology outpatient appointment was 4.9 years (interquartile range \[IQR\] 0.2--12.4 years), 72 % (1520) were female, and the patients' mean age at their gastroenterology appointment was 51.8 years (95 % CI 51.2--52.5 years).Table 1Demographics for all patients within the CPRD with IBS and appropriate HES data available for analysis; those referred to gastroenterology for the first time in 2008 or 2009; and those patients with 3 full years of data available before and after referralAll IBS cases defined within the CPRD with available and reliable HES data (see Fig. [1](#Fig1){ref-type="fig"})All IBS patients in the CPRD referred to gastroenterology in 2008 or 2009IBS patients in the CPRD referred to gastroenterology in 2008 or 2009 with 3 years of data either side of the appointmentTotal number of IBS patients in the cohort191,78848092076Sex Male48,840 (25)1335 (27.8)556 (26.8) Female142,948 (75)3474 (72.2)1520 (73.2)Age at gastroenterology outpatient appointment, years Mean (95 % CI)NA^a^50.2 (49.7--50.6)51.8 (51.2--52.5) 18--29--669 (14)195 (9) 30--49--1729 (36)748 (36) 50--75--2411 (50)1133 (55)Years from IBS diagnosis to referral Median (IQR)NA^a^4.4 (0.1--12.1)4.9 (0.2--12.4) IBS diagnosis at or following GI appointment--1086 (23)450 (22) Within first year--645 (13)257 (12) 1--2--256 (5)107 (5) 2--5--527 (11)222 (11) 5--10--815 (17)358 (17) More than 10--1480 (31)682 (33)SES: quintile according to Index of Multiple Deprivation 1 (least)47,330 (25)1194 (25)569 (28) 244,946 (24)1107 (23)462 (22) 337,871 (20)899 (19)386 (19) 433,998 (18)877 (18)344 (17) 5 (most)26,156 (14)706 (15)302 (15)Smoking Smokers43,152 (23)1087 (23)501 (24)Comorbidities Charlson score of 1 or greater44,111 (23)1195 (25)527 (25)Data are expressed as *n* (%) unless otherwise specified*CPRD* Clinical Practice Research Datalink, *IBS* irritable bowel syndrome, *HES* Hospital Episode Statistics, *NA* not applicable, *CI* confidence interval, *IQR* interquartile range, *GI* gastrointestinal^a^Only 11 % of these patients have a referral, therefore these variables are not relevant

Healthcare Utilisation {#Sec11}
----------------------

Increasing age and having IBS for longer than 2 years before referral to gastroenterology were both associated with increased primary care attendance, prescriptions and outpatient appointments (Table [2](#Tab2){ref-type="table"}). Women utilised 26 % more primary care services, 21 % more outpatient services and had 35 % more prescriptions relative to men. There was no statistically significant difference in the rates of colonoscopies or inpatient admissions according to sex or age at referral. Rates of utilisation in all domains of healthcare, with the exception of colonoscopy, increased with improved deprivation. Rates of colonoscopy were almost double in nonsmokers, while rates of utilisation in all other healthcare domains were 7--40 % higher in smokers. The presence of comorbid conditions increased patients' healthcare utilisation in all domains, with the exception of colonoscopy, by approximately 20 % (Table [2](#Tab2){ref-type="table"}).Table 2Adjusted rate ratios for overall healthcare utilisation according to patient demographicsVariablesRate ratios (95 % CI)Primary care attendancesPrescriptionsOutpatient appointmentsInpatient and day-case admissionsColonoscopySex Male---------- Female**1.261.351.21**1.030.80(1.24--1.27)(1.32--1.37)(1.18--1.24)(0.95--1.11)(0.60--1.07)Age at referral, years 18--29---------- 30--49**1.06** (1.03--1.080**1.13** (1.10--1.17)**1.29** (1.23--1.36)0.93 (0.83--1.04)1.27 (0.71--2.27) 50--75**1.24** (1.21--1.27)**1.86** (1.80--1.92)**1.40** (1.33--1.46)1.04 (0.93--1.16)1.54 (0.87--2.76)Duration of IBS before gastroenterology appointment, years Diagnosed at or following GI visit---------- \<11.02 (0.99--1.05)1.03 (1.00--1.07)1.05 (0.97--1.11)1.00 (0.91--1.15)0.99 (0.48--2.12) 1--2**1.05** (1.02--1.09)1.01 (0.96--1.05)0.99 (0.94--1.05)1.14 (0.99--1.31)1.12 (0.60--2.06) 2--5**1.20** (1.17--1.22)**1.34** (1.30--1.38)**1.22** (1.18--1.27)**1.12** (1.01--1.24)1.14 (0.71--1.82) 5--10**1.09** (1.07--1.11)**1.15** (1.12--1.18)**1.10** (1.06--1.14)0.96 (0.86--1.06)0.81 (0.51--1.28) \>10**1.15** (1.14--1.18)**1.28** (1.25--1.31)**1.19** (1.15--1.23)**1.39** (1.25--1.54)0.96 (0.66--1.40)Socioeconomic status Quintile 1 (highest)---------- Quintile 2**1.13** (1.11--1.14)**1.08** (1.06--1.11)**1.09** (1.05--1.12)1.04 (0.94--1.15)**1.86** (1.27--2.73) Quintile 3**1.09** (1.07--1.10)**1.22** (1.19--1.25)**1.06** (1.02--1.09)**1.13** (1.02--1.25)**1.84** (1.23--2.76) Quintile 4**1.17** (1.15--1.19)**1.20** (1.17--1.23)**1.23** (1.19--1.27)**1.23** (1.11--1.36)0.98 (0.59--1.61) Quintile 5 (lowest)**1.19** (1.16--1.21)**1.42** (1.39--1.46)**1.20** (1.63--1.25)**1.34** (1.19--1.47)1.40 (0.88--2.24)Smoking Nonsmoker---------- Smoker**1.19** (1.18--1.21)**1.40** (1.37--1.46)**1.07** (1.05--1.10)**1.13** (1.05--1.22)**0.57** (0.39--0.82)Comorbidity Score of 0 on Charlson index---------- Score of 1 or greater on Charlson index**1.19** (1.18--1.21)**1.22** (1.20--1.24)**1.23** (1.20--1.26)**1.18** (1.10--1.27)0.87 (0.63--1.19)Statistically significant ratios with a *p* value \<0.05 are shown in bold*CI* confidence interval, *IBS* irritable bowel syndrome, *GI* gastrointestinal

Over time, primary care utilisation, hospital inpatient, day-case admissions, outpatient appointments and colonoscopy rates all showed a similar pattern of utilisation, increasing before referral and peaking around the first gastroenterology appointment. The rates subsequently fell, but remained higher than pre-referral level (Table [3](#Tab3){ref-type="table"}). Prescriptions have substantially higher rates in the years following referral compared with the years before referral. When considering the absolute difference, compared with 3 years before referral, there were 15 extra prescriptions per person per year (increased from 26 to 41) 3 years after referral. For every two patients, there were three extra primary care and three extra outpatient appointments.Table 3Annual rates of healthcare utilisation per person per year for 3 years before and after the first gastroenterology appointmentHealthcare domainTime from first gastroenterology outpatient appointment3 years before2 years before1 year before1 year after2 years after3 years afterPrimary care attendances Rate per person per year (95 % CI)8.1 (8.0--8.3)8.4 (8.3 to 8.6)10.7 (10.5--10.8)9.7 (9.6--9.9)9.1 (8.9--9.2)9.7 (9.6--9.9) Absolute difference in attendances (95 % CI)Baseline0.3 (0.1 to 0.5)2.6 (2.4--2.8)1.6 (1.4--1.8)1.0 (0.8--1.2)1.6 (1.4--1.8)Prescriptions Rate per person per year (95 % CI)26.2 (24.7--27.7)29.3 (27.6 to 31.1)31.9 (30.0--33.8)35.9 (33.8--38.0)38.3 (36.1--40.6)40.7 (38.3--43.1) Absolute difference in prescriptions (95 % CI)Baseline3.1 (2.8 to 3.4)5.7 (5.4--6.0)9.7 (9.4--10.0)12.1 (11.8--12.5)14.5 (14.1--14.9)Outpatient appointments Rate per person per year (95 % CI)1.9 (1.7--2.0)2.1 (2.0 to 2.3)2.6 (2.4--2.8)3.9 (3.7--4.2)3.4 (3.2--3.6)3.4 (3.1--3.6) Absolute difference in attendances (95 % CI)Baseline0.2 (0.1 to 0.3)0.7 (0.6--0.8)2.0 (1.9--2.1)1.5 (1.4--1.6)1.5 (1.4--1.6)Hospital admissions per 10 people per year Rate per person per year (95 % CI)3.4 (2.9--3.9)3.5 (3.1 to 4.0)6.2 (5.6--6.8)7.8 (7.2--8.4)4.9 (4.3--5.5)3.9 (3.4--4.5) Absolute difference in admissions (95 % CI)Baseline0.1 (−0.2 to 0.5)2.8 (2.4--3.2)4.4 (3.9--4.9)1.5 (1.1--1.9)0.5 (0.1--0.9)Colonoscopies per 10 people per year Rate per person per year (95 % CI)0.1^a^ (0.1--0.2)0.2 (0.2 to 0.3)0.7 (0.6--0.8)1.9 (1.7--2.1)0.3 (0.2--0.3)0.3 (0.2--0.4) Absolute difference in colonoscopies (95 % CI)Baseline0.1 (0.0 to 0.2)0.6 (0.5--0.7)1.8 (1.6--2.0)0.2 (0.1--0.3)0.2 (0.1--0.3)*IBS* irritable bowel syndrome, *CI* confidence interval^a^Rate of 0.1 colonoscopies/10 people/year = 1 in 100 IBS patients having a colonoscopy in that year

Costs {#Sec12}
-----

Overall healthcare costs per patient increased by less than 25 % in the 3 years leading up to the first gastroenterology appointment (total mean individual cost increased by £772 (95 % CI £769--776) (Table [4](#Tab4){ref-type="table"}). In the first year following, overall costs were £1393 higher than at baseline (95 % CI £1389--1396) and £625 higher than the year before gastroenterology appointment. After 3 years following referral, total costs per person remained one-third higher than they were 3 years before referral, i.e. £3567 compared with £2323, an increase of £1244 (95 % CI £1240--1248). Figure [2](#Fig2){ref-type="fig"} shows the proportion of these costs each year that corresponded to each domain. Prescriptions accounted for over half of the total cost each year. Tables [5](#Tab5){ref-type="table"} and [6](#Tab6){ref-type="table"} show the stratified costs with gamma distribution parameters. The stratified data show similar patterns in costs as the RRs earlier described.Table 4Mean individual annual cost of healthcare utilisation and absolute difference for annual total cost compared with 3 years before the first gastroenterology appointmentMean individual annual cost (£) \[Gamma distribution α, λ (E−04)\]Time from first gastroenterology outpatient appointment3 years before2 years before1 year before1 year after2 years after3 years afterPrimary care attendances302.50 \[1.467--48.49\]312.47 \[1.519--48.60\]381.37 \[2.063--54.10\]356.15 \[1.567--46.53\]329.25 \[1.507--45.76\]335.6 \[1.318--39.28\]Prescriptions1538.19 \[0.400--2.60\]1717.92 \[0.376--2.19\]1937.03 \[0.418--2.16\]2165.69 \[0.393--1.81\]2371.73 \[0.409--1.72\]2513.9 \[0.379--1.51\]Outpatient appointments182.38 \[0.369--20.23\]198.41 \[0.415--20.19\]242.13 \[0.446--18.40\]618.1 \[1.760--28.48\]307.43 \[0.520--16.90\]298.35 \[0.444--14.89\]Inpatient and day-case admissions296.35 \[0.060--2.02\]301.69 \[0.068--2.27\]511.81 \[0.096--1.87\]505.62 \[0.126--4.29\]456.47 \[0.076--1.66\]410.37 \[0.053--1.29\]Colonoscopies3.13 \[0.007--22.95\]6.02 \[0.016--27.28\]22.57 \[0.059--26.09\]74.75 \[0.211--28.27\]7.26 \[0.018--24.43\]8.81 \[0.021--23.82\]Total2322.55 \[0.575--2.48\]2536.52 \[0.566--2.23\]3094.92 \[0.635--2.05\]3720.31 \[0.797--2.14\]3472.14 \[0.580--1.67\]3567.03 \[0.511--1.43\]Mean over 3 years2651.33 \[1.766--2.22\]3589.49 \[1.836--1.71\]Mean absolute cost difference (£) \[95 % CI\] Annual total costBaseline213.97 \[210.97--216.97\]772.37 \[769.20--775.54\]1392.94 \[1389.60--1396.29\]1149.59 \[1146.32--1152.87\]1244.48 \[1240.18--1247.78\] Total cost over 3 yearsBaseline935.16 \[928.09--941.89\]All costs approximated a gamma distribution, therefore α (mean^2^/sd^2^) and λ (mean/sd^2^) parameters are shown for each stratum*CI* confidence intervalFig. 2Total mean individual cost each year and the contribution of each component of care to the totalTable 5Mean total and stratified costs in the 3 years before gastroenterology appointmentVariables3 years before2 years beforeYear beforeMean cost (£)Gamma distribution parametersMean cost (£)Gamma distribution parametersMean cost (£)Gamma distribution parametersαλ (E−04)αλ (E−04)αλ (E−04)Sex Male1817.850.5212.861870.640.5923.162470.630.5492.22 Female2498.560.6042.422772.550.5872.123319.430.6752.03Age at referral, years 18--291087.850.3673.381199.160.3973.311705.340.6213.64 30--491689.190.4342.571816.550.3942.172375.270.3981.67 50--752780.30.6582.363081.770.6752.193804.210.9062.38Duration of IBS before gastroenterology appointment, years Diagnosed at GI visit1838.440.4042.202017.910.4502.232576.350.4481.74 ≤11477.070.4483.031687.560.5533.272525.640.4851.92 \>1--21865.150.6583.532079.950.5842.812565.720.6512.54 \>2--53084.40.5791.883087.140.5351.733707.280.7361.99 \>5--102320.970.5672.442700.110.5021.863123.860.6592.11 \>102761.260.8262.992993.680.7902.643518.980.8172.32Socioeconomic status Quintile 11910.210.5332.792140.470.6162.882664.620.6132.30 Quintile 22154.370.5752.672386.590.5212.182770.690.6702.42 Quintile 32387.750.6382.672579.910.6732.613064.040.8832.88 Quintile 42564.550.5702.222780.610.5862.113563.490.4941.39 Quintile 53006.90.6602.193220.690.5491.713914.920.7801.99Smoking Nonsmoker2129.810.5172.432316.080.4712.032807.320.5551.98 Smoker2906.560.7812.693214.220.9633.003996.170.9542.39Comorbidity (according to Charlson score) Score of 02202.980.5482.492399.620.5112.132936.730.5872.00 Score of 1 or greater2666.330.6602.482936.890.7502.553558.360.7952.23All costs approximated a gamma distribution, therefore α (mean^2^/sd^2^) and λ (mean/sd^2^) parameters are shown for each stratum*IBS* irritable bowel syndrome, *GI* gastrointestinalTable 6Mean total and stratified costs in the 3 years after gastroenterology appointmentVariablesYear after2 years after3 years afterMean cost (£)Gamma distribution parametersMean cost (£)Gamma distribution parametersMean cost (£)Gamma distribution parametersα*λ* (E−04)α*λ* (E−04)α*λ* (E−04)Sex Male2909.770.7382.542926.050.5401.852993.080.4721.58 Female3689.360.7031.903664.940.5991.633773.380.5301.40Age at referral, years 18--292202.990.6292.861646.940.5733.481494.980.5033.37 30--492715.760.5051.862719.020.3931.442822.170.2700.96 50--755733.741.8593.244048.320.6941.714162.510.7251.74Duration of IBS before gastroenterology appointment, years Diagnosed at GI visit3238.050.6271.933145.460.4111.313298.310.2410.73 \<12937.960.6722.292346.750.4401.872504.390.5162.06 1--23176.751.2563.952364.430.7203.042349.720.7163.05 2--54502.850.9012.004005.880.6571.643844.450.6171.60 5--103803.450.9542.513517.310.7242.063658.140.6441.76 \>104120.240.8602.094072.910.7061.734183.910.8472.02Socioeconomic status Quintile 13219.410.8922.773044.860.6162.022367.60.3901.65 Quintile 23482.040.6701.923130.480.4491.433152.920.6702.13 Quintile 33785.390.9092.403624.10.7332.023801.640.4061.07 Quintile 44223.210.6901.633804.110.5381.413976.080.4861.22 Quintile 54377.851.4823.394258.90.6991.644583.850.5821.27Smoking Nonsmoker3414.480.7262.133105.280.5091.643132.320.5341.71 Smoker4681.731.0822.314610.450.8541.854918.380.5651.15Comorbidity (according to Charlson score) Score of 03492.880.7462.143270.070.5341.633319.780.5391.62 Score of 1 or greater4388.770.9742.224062.40.7281.794285.150.4941.15All costs approximated a gamma distribution, therefore α (mean^2^/sd^2^) and λ (mean/sd^2^) parameters are shown for each stratum*IBS* irritable bowel syndrome, *GI* gastrointestinal

Discussion {#Sec13}
==========

This study demonstrates that the linked CPRD and HES data can be used to measure rates and change in healthcare utilisation with precise costs for patients. Using linked data of this type will potentially improve the validity of economic models considering complex healthcare interventions in real populations. Absolute difference in annual utilisation is important to measure for most economic evaluations. We have been able to use these data to calculate the difference in rates of inpatient, outpatient, and primary care and prescriptions before and after an intervention. Similarly, we have been able to attach the exact cost for each patient's specific care use across the domains of healthcare for which the NHS is the payer. The data available within these datasets allowed the generation of stratified outcomes, useful for scenario analyses. We have reported costs with the appropriate distribution parameter values, suitable to input into economic modelling. Generating these parameters directly from the data without requiring any assumptions provides realistic parameters for probabilistic sensitivity analyses.

Previous Studies {#Sec14}
----------------

The CPRD (known as the General Practice Research Database until 2012 \[[@CR26]\]) and linked HES are well-established data sources for epidemiological and pharmacovigilance studies \[[@CR27], [@CR28]\]. Primary care data from the CPRD were first used as part of a cost-burden study 25 years ago \[[@CR29]\], before reimbursement using HRGs was introduced (2003) and before HES-linked data were available (2008). In addition, before this linkage was available, but since costs have been calculated using HRGs, a series of studies comparing the comparative effectiveness and costs of various treatments for glaucoma were conducted \[[@CR30]--[@CR33]\]. These studies extracted utilisation data from the CPRD, but without HES linkage they used data within the CPRD referral file as evidence of secondary care attendance. This method has continued to be used following the linkage \[[@CR34]--[@CR39]\], but it misses events and the timing of events is less accurate than using HES data \[[@CR40]\]. Our study was the first to use HES data to directly assess inpatient and outpatient secondary care use linked to the CPRD as the source of primary care use. Unit costs have been used in previous studies in place of calculating HRGs \[[@CR30]--[@CR36], [@CR41]\]. The unit costs provide the national average cost of each type of care episode, whilst the HRG gives the specific cost generated by that patient for that event. Consequently, the HRGs provide a far more precise cost estimate, but patient-specific HRGs cannot be calculated in the absence of the HES data.

Strengths of These Linked Datasets {#Sec15}
----------------------------------

The large number of patient records contained within these datasets is a great strength. It allows both greater precision of utilisation and cost estimates and stratification by many variables with adequate power. Within this study, it has meant that we have been able to demand a number of eligibility criteria for cases without any substantial loss of heterogeneity (Table [1](#Tab1){ref-type="table"}). This ability to stratify outcomes by a number of clinically relevant variables will reduce both structural and parameter assumptions when using these data within economic models. Not only this, but also our analysis, has shown that the heterogeneity of patients within the specific community where the intervention is implemented can be defined. This will be of increasing value given the current interest in stratified or personalised medicine and the need to find those people for whom interventions are most cost effective \[[@CR42], [@CR43]\].

When we downloaded the CPRD and HES-linked datasets for this study, we had data available in all healthcare domains for at least 8 years. These datasets now have at least 10 years of data for all domains and up to 30 years in primary care and prescriptions. This allows follow-up of patients for much greater durations than usually possible with randomised controlled trials (RCTs). Even though patients move between primary care practices, on registering with a CPRD-linked practice all their significant previous diagnoses are loaded into the CPRD record. The HES data are lifelong. The duration of these records is also therefore greater than in insurance datasets. Alongside this, although not accessed for this study, death registry data are linked to CPRD records. The duration of follow-up reduces the need for extensive assumptions and predictions regarding long-term outcomes, which can reduce transparency and increase uncertainty and bias \[[@CR44], [@CR45]\].

The data within these datasets are generated through routine care. They reflect actual clinical practice rather than the closely controlled setting of RCTs. RCTs can be highly selected, with outcomes that are not replicated in general clinical practice \[[@CR46]\]. For economic evaluation, this means that predictions and expectations based on such data are not realised \[[@CR47]\]. The real-world nature of the data in the CPRD and HES means the outcomes are readily generalisable. These databases are also more generalisable to the whole population than results of similar studies from insurance claims data. The NHS provides universal healthcare, unlike insurance companies. Datasets from these organisations are limited to people eligible for public insurance or individuals insured by one provider, and the terms of their insurance cover, for instance which facilities they can access and when, may cause patients to change their healthcare utilisation behaviour.

CPRD and HES data are relatively easily available on application to the administrators; the cost data are all publicly available. The nature of these data and the potential to directly link costs to them make studies relatively cheap and quick to replicate. Thus, policy outcomes can be efficiently analysed as well as the predictions of cost-effectiveness analyses in the postmarketing of drugs and devices.

Weaknesses of These Linked Datasets {#Sec16}
-----------------------------------

One of the greatest weaknesses of using routinely collected data is missing data. The CPRD is audited on a regular basis to ensure that the data recorded are complete and accurate \[[@CR4], [@CR18]\]. Despite this, in fewer than 5 % of records event dates are not recorded or diagnostic codes are missing. This was higher in the HES outpatient data (12 %). The missingness of these data is likely to be random. Consequently, in this study we had sufficient data to exclude those records. Other data are not recorded at all. One example from this study was disease severity. For other conditions, diagnostic codes or other recorded information such as investigation results indicate disease severity, but for IBS there are no such data. Similarly, within these datasets no data record symptom improvement or quality-of-life information. This means that for diseases such as IBS with no attributable mortality or pathophysiological measurement, deterioration or improvement is unknown. This makes deriving disease-state transition probabilities very difficult in conditions such as IBS. In other conditions with clearly demarcated disease states, the proportion of a cohort in each state over time would be easier to define.

A limitation of any electronic database study within healthcare is the difficulty in verifying coding accuracy. CPRD data are regularly audited to ensure their quality \[[@CR18]\]. Many studies have assessed the internal validity of CPRD coding, using either algorithms or sensitivity analyses, and the external validity by directly reviewing patient records or sending general practitioners questionnaires \[[@CR48], [@CR49]\]. Over a range of 183 diagnoses, the median proportion of cases confirmed was 89 % \[[@CR48]\]. Coding for IBS specifically has been validated via questionnaires to general practitioners, who confirmed IBS diagnosis in 99 % of patients with a first IBS code whilst enrolled at that practice, and 84 % of patients with an IBS code from a previous practice \[[@CR50]\]. Individual coding errors are likely to be independent of any intervention or population analysed, and independent of cost. Consequently, it is unlikely that differential misclassification from inaccurate coding occurs at an individual level. However, it is likely that changes in external factors that link recorded outcomes to reimbursement change the accuracy and frequency of coding, which could introduce bias \[[@CR51], [@CR52]\].

Within these datasets, the duration of patient enrolment varies. We had sufficient cases to restrict our analysis to only those patients with 3 full years of data either side of the first gastroenterology appointment. Limiting our population could introduce selection bias towards relatively well patients and those less likely to move, such as older patients. This would not be an appropriate approach if the condition under investigation had associated mortality impact, but IBS does not. Comparing all eligible patients with gastroenterology appointments in 2008 or 2009 with those who had data available for the full 6 years (Table [1](#Tab1){ref-type="table"}), the demographics remain broadly similar. There is evidence of proportionally fewer patients aged under 30 years being eligible but this has little effect on the mean age of the sample. In situations where survival (or mortality) was important, or selecting only patients with complete years of data would cause substantial selection bias, inverse probability weighting of costs would be an appropriate method for analysis \[[@CR53]\].

The nature of the CPRD and HES datasets mean that the utilisation data and associated costs are from the payer's perspective only. In the current climate, this is adequate for Health Technology Assessments. If conducting an analysis of societal impact, then additional data from other sources would be required. Likewise, these data are UK-specific, which might limit generalisability outside the NHS. For similarly organised healthcare systems, it is feasible to attach other system-specific costing structures to the utilisation data but this would need further analysis.

A gastroenterology appointment for IBS diagnosis or management is not currently recommended as best practice \[[@CR9], [@CR12]\] therefore referral from primary care is not standardised. Consequently, the patients who see a gastroenterologist are likely to be systematically different to those who do not. It is for this reason that we used a before and after study design. However, these data cannot establish the counterfactual utilisation and cost trajectories in the absence of a gastroenterology appointment. For instance, it is possible that utilisation and costs increase in these patients if they do not visit a gastroenterologist. Comparing these patients with IBS to those never referred would lead to confounding by indication. This is a limitation of the data in these databases compared with RCT data. Propensity score matching has gained popularity for assessing the probability of intervention allocation according to baseline covariates \[[@CR54]\]. This method relies on known and measured variables, at least partially explaining differences between those referred and not referred. Table [1](#Tab1){ref-type="table"} shows that the demographic variables we measured were similar between the referred and nonreferred patients, which makes propensity score matching less useful here. It has previously been found that the factors most likely to predict referral to a gastroenterologist are reporting stress worsening symptoms and having more than three bowel movements per day, which are not variables recorded within the CPRD and HES dataset \[[@CR13]\]. Alternatively, epoch analysis aims to estimate causal effect when patients switch interventions during longitudinal observational studies \[[@CR55]\]. However, in our study, referral to gastroenterology is a once-only intervention. Patients who are 'never referred' can become 'referred', but not vice versa. Thus, to use these datasets to assess the potential cost effectiveness of referring patients with IBS to gastroenterology, assumptions regarding utilisation and costs in the absence of a gastroenterology referral should be included in a scenario analysis. As these datasets develop, their strengths in size and in reflecting actual clinical practice can be maintained by conducting a randomised trial prospectively through the CPRD general practices \[[@CR56]\]. For instance, it is now possible to alert CPRD-linked general practitioners through their electronic records system when they consult patients potentially eligible for a trial \[[@CR56], [@CR57]\].

The lack of linked quality-of-life data within these datasets means that linking the utilisation and cost outcomes with other sources of quality-of-life data for a cost-effectiveness study will be challenging. However, we acknowledge that this would be less difficult in conditions with well-defined disease progression indicators recorded within routine healthcare data. We have demonstrated the greatest strength in these data is the capacity to define patient-level demographic factors, comorbidities and risk factors, and link them with specific costs. The potential for these data is substantial. Individual-level simulations using these data could directly sample individuals, avoiding the need to generate hypothetical 'patients' from parameter distributions \[[@CR58]\], and might provide better adjustment for unknown confounders \[[@CR59], [@CR60]\]. There is also great interest in the potential of real-world electronic health data for validating economic model predictions \[[@CR61]\]. The large numbers of records available with data that allow characterisation of patient heterogeneity will become more useful with increasing stratification of patient's treatment according to risk factors or predictors of response.

Conclusions {#Sec17}
===========

These linked datasets provide useful data for large numbers of patients, which allows stratification of costs and new insights into healthcare utilisation. It is possible to derive relevant parameters and distributions directly from the population of interest. We advise caution when choosing to use these datasets, depending on the disease investigated, if the aim is to use the outcomes generated in cost-effectiveness analysis. The important disease states, or markers of them, should be events routinely recorded in healthcare data so states can be adequately characterised and linked to quality-of-life data from other sources.
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